02:30 , May 18, 2018 |  BC Week In Review  |  Financial News

Polyphor raises $155.3M Swiss IPO

Polyphor Ltd. (SIX:POLN) gained CHF0.20 to CHF38.20 in its first day of trading on May 15 after raising CHF155 million ($155.3 million) through the sale of 4.1 million shares at CHF38 in an IPO on...
16:59 , May 15, 2018 |  BC Extra  |  Financial News

Polyphor ticks up after Swiss IPO

Polyphor Ltd. (SIX:POLN) gained CHF0.20 to CHF38.20 in its first day of trading Tuesday after raising CHF155 million ($155.3 million) through the sale of 4.1 million shares at CHF38 in an IPO on the SIX...
07:00 , Jun 4, 2012 |  BioCentury  |  Emerging Company Profile

ProteoMediX: Prostate's PI3K biomarkers

ProteoMedix AG is developing a multiplexed ELISA-based blood test that aims to confirm an initial PSA positive result and reduce unneeded biopsies by monitoring a quartet of biomarkers associated with alterations in PI3K signaling, a...
08:00 , Nov 7, 2011 |  BC Week In Review  |  Financial News

Biognosys completes venture financing

Biognosys AG , Schlieren, Switzerland   Business: Proteomics   Date completed: 10/31/11   Type: Venture financing   Raised: CHF2.7 million ($3.1 million)   Investors: Syngenta; Redalpine Capital I; Cantonal Bank of Zurich; individual investors  ...
08:00 , Jan 28, 2002 |  BioCentury  |  Finance

Ebb & Flow

ImClone's fall appeared to hit a sordid bottom on Thursday with a "tell-all" story in The New York Times that ventured into the personal lives of the company's management. But IMCL filed several 8-Ks on...
08:00 , Jan 23, 2002 |  BC Extra  |  Financial News

Cytos raises $27 million

Proteomics and high throughput screening company Cytos Biotechnology (Zurich, Switzerland) closed a third financing round, raising CHF45 million ($27 million) through the sale of 5,087 new shares. The round, led by HBM BioVentures, included Equity4Life;...